Nurix Therapeutics, Inc.

NasdaqGM:NRIX 주식 리포트

시가총액: US$2.6b

Nurix Therapeutics 경영진

경영진 기준 점검 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

핵심 정보

Arthur Sands

최고경영자

US$6.4m

총 보수

CEO 급여 비율10.58%
CEO 재임 기간12yrs
CEO 지분 보유율0.7%
경영진 평균 재임 기간6.2yrs
이사회 평균 재임 기간4.5yrs

최근 경영진 업데이트

Recent updates

Seeking Alpha • Aug 24

Nurix Therapeutics: Roche Has Changed The Economics Of The Bull Case

Summary Nurix secures a transformative Roche partnership, gaining $700M upfront, 50% U.S. profit share, and 60% Roche-funded global development for bexobrutideg. NRIX's financial runway is extended to ~3.5 years, reducing near-term dilution risk and enabling multi-indication expansion without sacrificing U.S. economics. Bexobrutideg's Phase 1 data show high response rates in CLL/SLL, with a pivotal Phase 3 trial aiming to demonstrate superiority over pirtobrutinib. NRIX's DEL-AI platform advances with Sanofi and Gilead partnerships, providing milestone optionality beyond the BTK franchise. Read the full article on Seeking Alpha
분석 기사 • Nov 16

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shareholders have had their patience rewarded with a 30% share price jump in...
분석 기사 • Oct 12

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) missed earnings with its latest quarterly results, disappointing...
분석 기사 • Sep 30

Subdued Growth No Barrier To Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Price

With a median price-to-sales (or "P/S") ratio of close to 10x in the Biotechs industry in the United States, you could...
분석 기사 • Aug 18

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

NasdaqGM:NRIX 1 Year Share Price vs Fair Value Explore Nurix Therapeutics's Fair Values from the Community and select...
분석 기사 • Jul 14

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shareholders will have a reason to smile today, with the analysts making...
분석 기사 • May 12

Shareholders Will Probably Hold Off On Increasing Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) CEO Compensation For The Time Being

Key Insights Nurix Therapeutics' Annual General Meeting to take place on 19th of May CEO Arthur Sands' total...
Seeking Alpha • Apr 17

Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential

Summary FDA IND clearance given for BTK degrader GS-6791, targeting inflammatory disorders, allowing Nurix Therapeutics, Inc. to receive a $5 million milestone payment from Gilead Sciences. Nurix has earned $135 million from its Gilead collaboration and could earn up to a total of $420 million in milestone payments for developing up to five protein degraders. Nurix's wholly owned BTK degrader Bexobrutideg is in phase 1b trials for relapsed/refractory B-cell malignancies, with plans to target inflammatory and autoimmune disorders as well. Besides the partnership with Gilead Sciences, the company is advancing its STAT6 protein degrader with Sanofi and antibody drug conjugate degraders as a new class of drugs to target disorders with Pfizer. Read the full article on Seeking Alpha
분석 기사 • Apr 17

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shareholders will have a reason to smile today, with the analysts making...
분석 기사 • Mar 22

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely

Unfortunately for some shareholders, the Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) share price has dived 25% in the last...
Seeking Alpha • Feb 18

Nurix Therapeutics: A Story To Monitor

Summary Nurix Therapeutics, Inc.'s shares have dropped some 40% due to limited 2025 data catalysts, despite promising Phase 1 results for NX-5948 in CLL, targeting pivotal trials in 2025. Nurix's DELigase platform leverages E3 ligases for protein modulation, aiming to degrade or elevate proteins, offering advantages over CRISPR and RNA interference methods. NX-5948 shows strong efficacy in heavily pre-treated CLL patients, with Fast Track and PRIME designations, but faces competition from BeiGene's similar BTK degrader. An initial analysis around NRIX stock follows in the paragraphs below. Read the full article on Seeking Alpha
분석 기사 • Jan 30

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. By way of example, Nurix Therapeutics...
Seeking Alpha • Jan 05

Nurix Therapeutics: Still A Cool Story, But This Price Point Remains Too Hot For Me

Summary Nurix Therapeutics (NRIX) focuses on protein degradation in cancer treatment, with a current valuation of $1.4 billion and promising early-stage clinical data. NX-5948, a BTK degrader, shows high response rates in B-cell malignancies, with manageable safety profiles and FDA Fast Track designations. Financially, NRIX holds $99 million in cash and $349 million in marketable securities, but faces risks of future dilution and high execution expectations. Despite compelling early data, NRIX's high valuation and market hype suggest waiting for better entry points, making it a "Hold" for now, in my opinion. Read the full article on Seeking Alpha
분석 기사 • Nov 07

Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25%

Despite an already strong run, Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shares have been powering on, with a gain of...
분석 기사 • Oct 31

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Nurix...
Seeking Alpha • Oct 08

Nurix: An Attractive Early-Stage Biotech Play

Summary Nurix Therapeutics, specializing in targeted protein degradation, shows promise with its clinical-stage candidates NX-1607, NX-5948, and NX-2127 for cancer and autoimmune diseases. Strong partnerships with Sanofi, Gilead, and Pfizer bolster Nurix's funding and technological capabilities, enhancing its potential for successful drug development and commercialization. Despite operating at a loss, Nurix's solid cash position and positive clinical trial results make it a compelling buy opportunity, though risks remain. Nurix's innovative approach and potential regulatory approvals make it a strong investment candidate for those seeking high-risk, high-reward opportunities. Read the full article on Seeking Alpha
분석 기사 • Sep 07

Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Nurix Therapeutics, Inc.'s ( NASDAQ:NRIX ) price-to-sales (or "P/S") ratio of 24.1x might make it look like a strong...
Seeking Alpha • Sep 04

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Summary Nurix Therapeutics leverages the ubiquitin-proteasome system for targeted protein degradation (TPD) and elevation (TPE) in cancer and autoimmune diseases, with promising early-stage clinical data. Key programs include BTK, IKZF, and CBL-B targets, with notable molecules NX-5948, NX-2127, and NX-1607 showing potential in heavily pretreated B-cell malignancies. Strategic partnerships with Gilead, Sanofi, and Pfizer provide substantial financial backing, with up to $8.1 billion in potential milestone payments. Despite high valuation and limited near-term data catalysts, Nurix's innovative approach and big pharma interest warrant continued observation for future investment opportunities. Read the full article on Seeking Alpha
분석 기사 • Jul 15

Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, Nurix Therapeutics...
Seeking Alpha • Jun 19

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Summary Nurix Therapeutics raised $209m in its IPO in July 2020, focusing on protein degradation in drug development, primarily in the blood cancer space. Protein degradation involves marking proteins for destruction by the proteasome using bifunctional small molecules. Nurix's lead proprietary candidate NX-5948 showed promising results in a Phase 1a clinical study for CLL patients in data released this week, triggering a surge in the company's share price. Management hopes to guide its lead candidate into a pivotal study next year, opening up a potentially compelling market opportunity. More data - in NHL and immuno-oncology - will arrive this year, and Nurix continues to collaborate with three major Pharma companies - Gilead, Sanofi, and Pfizer. The bull run can therefore be sustained. Read the full article on Seeking Alpha
분석 기사 • May 29

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

The Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) share price has done very well over the last month, posting an excellent...
Seeking Alpha • Apr 15

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Summary Nurix Therapeutics raises $175 million in an upsized offering after a 168% stock return in the past six months. The biotech company is developing protein degraders, with NX-2127 and NX-5948, targeting B-cell malignancies. Nurix's protein degraders are focused on BTK, a target also addressed by Johnson & Johnson's popular drug Imbruvica. Hold rating advised: High-risk, high-reward due to innovative approach and competitive market; efficacy and safety data needed. Read the full article on Seeking Alpha
분석 기사 • Apr 14

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shares have continued their recent momentum with a 28% gain in the last month...
분석 기사 • Feb 20

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

With a price-to-sales (or "P/S") ratio of 6.3x Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) may be sending very bullish...
Seeking Alpha • Jan 16

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Summary Nurix Therapeutics remains a highly interesting science project, but the rubber has yet to hit the road on their clinical projects. The company's BTK degraders are showing early signs of life, but the competition in the market and expenses are concerns. Nurix has enough assets to fund operations for another 6 to 7 quarters, but a cash infusion may be needed later this year. Read the full article on Seeking Alpha
분석 기사 • Dec 29

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
분석 기사 • Oct 14

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

To the annoyance of some shareholders, Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shares are down a considerable 29% in...
분석 기사 • Oct 13

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Shareholders in Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) may be thrilled to learn that the analysts have just delivered...
분석 기사 • Sep 30

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO 보수 분석

Arthur Sands의 보수는 Nurix Therapeutics의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
May 31 2026n/an/a

-US$341m

Feb 28 2026n/an/a

-US$295m

Nov 30 2025US$6mUS$675k

-US$264m

Aug 31 2025n/an/a

-US$245m

May 31 2025n/an/a

-US$207m

Feb 28 2025n/an/a

-US$208m

Nov 30 2024US$6mUS$613k

-US$194m

Aug 31 2024n/an/a

-US$177m

May 31 2024n/an/a

-US$165m

Feb 29 2024n/an/a

-US$145m

Nov 30 2023US$4mUS$591k

-US$144m

Aug 31 2023n/an/a

-US$149m

May 31 2023n/an/a

-US$157m

Feb 28 2023n/an/a

-US$179m

Nov 30 2022US$9mUS$572k

-US$180m

Aug 31 2022n/an/a

-US$171m

May 31 2022n/an/a

-US$154m

Feb 28 2022n/an/a

-US$135m

Nov 30 2021US$5mUS$539k

-US$117m

Aug 31 2021n/an/a

-US$99m

May 31 2021n/an/a

-US$89m

Feb 28 2021n/an/a

-US$63m

Nov 30 2020US$17mUS$521k

-US$43m

Aug 31 2020n/an/a

-US$37m

May 31 2020n/an/a

-US$21m

Feb 29 2020n/an/a

-US$24m

Nov 30 2019US$1mUS$474k

-US$22m

보상 대 시장: Arthur의 총 보수(USD6.37M)는 US 시장에서 비슷한 규모 기업의 평균(USD6.99M) 수준입니다.

보상과 수익: Arthur의 보상은 회사가 적자임에도 증가했습니다.

CEO

Arthur Sands (64 yo)

12yrs
재임 기간
US$6,374,138
보수

Dr. Arthur T. Sands, M.D., Ph D., has been the Chief Executive Officer and Director of Nurix Therapeutics, Inc. (formerly, Nurix Inc.) since September 2014 and has been its President since June 2020. Dr. S...

리더십 팀

이름직위재임 기간보수지분
Arthur Sands
CEO, President & Director12yrsUS$6.37m0.73%
$ 19.0m
Johannes Van Houte
Chief Financial Officer10.5yrsUS$2.30m0.039%
$ 1.0m
Gwenn Hansen
Chief Scientific Officer6.3yrsUS$2.50m0.11%
$ 2.9m
Christine Ring
Chief Legal Officer7yrsUS$2.26m0.0088%
$ 228.7k
John Kuriyan
Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Arthur Weiss
Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Rita Kwong
Senior Accounting Managerno data데이터 없음데이터 없음
Pasit Phiasivongsa
Chief Technical Officer2.3yrs데이터 없음데이터 없음
Wesley Burwell
Chief Human Resources Officerless than a year데이터 없음데이터 없음
Jason Kantor
Chief Business Officer6.2yrs데이터 없음데이터 없음
Christopher Phelps
Senior VP & Head of Early Drug Discovery5.7yrs데이터 없음데이터 없음
Buckley Kohlhauff
Senior Vice President of Information Technology4.7yrs데이터 없음데이터 없음
6.2yrs
평균 재임 기간
60yo
평균 나이

경험이 풍부한 관리: NRIX의 경영진은 노련하고 경험이 풍부합니다(평균 재임 6.2 년).

이사회 구성원

이름직위재임 기간보수지분
Arthur Sands
CEO, President & Director12yrsUS$6.37m0.73%
$ 19.0m
John Kuriyan
Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Arthur Weiss
Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Julia Gregory
Independent Chairman7.1yrsUS$258.97k0.010%
$ 269.9k
Ronald Levy
Member of Medical Advisory Board3.7yrs데이터 없음데이터 없음
Judith Reinsdorf
Independent Director4.9yrsUS$229.07k0%
$ 0
Roy Baynes
Independent Director1.5yrsUS$668.79k0%
$ 0
David Lacey
Independent Director10.4yrsUS$226.57k0.032%
$ 836.7k
Paul Silva
Independent Director4.9yrsUS$230.32k0%
$ 0
Edward Saltzman
Independent Director4yrsUS$220.22k0%
$ 0
Roger Dansey
Independent Directorless than a yearUS$421.68k0%
$ 0
Anil Kapur
Independent Director1.9yrsUS$217.93k0%
$ 0
4.5yrs
평균 재임 기간
70yo
평균 나이

경험이 풍부한 이사회: NRIX의 이사회는 경험이 있음으로 간주됩니다(평균 재임 4.5 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/09/14 14:00
종가2026/09/11 00:00
수익2026/05/31
연간 수익2025/11/30

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Nurix Therapeutics, Inc.는 26명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Brian SkorneyBaird
Joel BeattyBaird
Zhiqiang ShuBerenberg